Pila Pharma AB
The answer first
Does Pila Pharma beat the market?
No, Pila Pharma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 26% of Nordic stocks
- Quality70
- Value13
- Trend34
No. 116 of 195 in healthcare
Max for seven days
Follow Pila Pharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Pila Pharma
Your first answer is free, no account needed.
Do you own Pila Pharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Pila Pharma and a few more. Free, no card.
Super Stock+44.6%In short
- Pila Pharma has fallen 27.5% over the past year, including dividends.
- Overall, Pila Pharma ranks better than 26% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 91.0%. The price is 86.2% below its peak now.
What do analysts think of Pila Pharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 26% of Nordic stocks.
No. 116 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 84 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.05
- Asset turnoverSales divided by everything the company owns0.07
- Return on equityProfit divided by equity−104.1%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 125 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity3.6
- P/SPrice divided by sales76.9
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 98 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−10.9%
- 6 months+5.7%
- 9 months+29.8%
- 12 months−27.5%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Pila Pharma
One fund we follow owns Pila Pharma. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Pila Pharma
Pila Pharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK.
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.


See the full analysis of Pila Pharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card